A case of possible drug-induced liver injury due to COVID-19 vaccine
Q4 Medicine
Soichiro Shimizu, Ken Sato, K. Ito, Aoi Kita, Kousuke Aihara, Y. Tateyama, T. Abe, M. Shibasaki, Setsuo Yamazaki, Y. Fukai, K. Iizuka, D. Takizawa, H. Arai, M. Ide, T. Uraoka
求助PDF
{"title":"A case of possible drug-induced liver injury due to COVID-19 vaccine","authors":"Soichiro Shimizu, Ken Sato, K. Ito, Aoi Kita, Kousuke Aihara, Y. Tateyama, T. Abe, M. Shibasaki, Setsuo Yamazaki, Y. Fukai, K. Iizuka, D. Takizawa, H. Arai, M. Ide, T. Uraoka","doi":"10.2957/kanzo.63.530","DOIUrl":null,"url":null,"abstract":"The patient presented with nausea, appetite loss, and fatigue. She had received two doses of Pfizer/BioN-Tech BNT162b2 mRNA vaccine (COMIRNATYR) for coronavirus disease 2019 (COVID-19). Acute liver injury was noted 14 days after the first dose of the vaccine. Re-exposure through the second dose worsened the liver injury. After liver biopsy on the third day of admission, methylprednisolone (1000 mg) was administered. Liver histology showed acute hepatitis with diffuse lobular inflammation/necrosis and lymphocyte-dominant infiltra-tion in the portal areas. The patient was diagnosed with drug-induced liver injury due to the COVID-19 vaccine based on the Digestive Disease Week Japan 2004 (DDW-J) scale, which assesses the temporal relationship, liver biopsy, and laboratory findings. With improvements in the blood test parameters, prednisolone was gradually tapered and stopped. One month later, no biochemical signs of relapse were noted. To our knowledge, this is the first report describing liver injury after the administration of the Pfizer COVID-19 vaccine in Japan. Copyright © 2022 The Japan Society of Hepatology.","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Hepatologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2957/kanzo.63.530","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
引用
批量引用
Abstract
The patient presented with nausea, appetite loss, and fatigue. She had received two doses of Pfizer/BioN-Tech BNT162b2 mRNA vaccine (COMIRNATYR) for coronavirus disease 2019 (COVID-19). Acute liver injury was noted 14 days after the first dose of the vaccine. Re-exposure through the second dose worsened the liver injury. After liver biopsy on the third day of admission, methylprednisolone (1000 mg) was administered. Liver histology showed acute hepatitis with diffuse lobular inflammation/necrosis and lymphocyte-dominant infiltra-tion in the portal areas. The patient was diagnosed with drug-induced liver injury due to the COVID-19 vaccine based on the Digestive Disease Week Japan 2004 (DDW-J) scale, which assesses the temporal relationship, liver biopsy, and laboratory findings. With improvements in the blood test parameters, prednisolone was gradually tapered and stopped. One month later, no biochemical signs of relapse were noted. To our knowledge, this is the first report describing liver injury after the administration of the Pfizer COVID-19 vaccine in Japan. Copyright © 2022 The Japan Society of Hepatology.
新冠肺炎疫苗可能致药物性肝损伤1例
病人表现为恶心、食欲不振和疲劳。她接受了两剂辉瑞/BioN-Tech 2019冠状病毒病(COVID-19) BNT162b2 mRNA疫苗(COMIRNATYR)。第一剂疫苗接种后14天出现急性肝损伤。第二剂量的再次暴露加重了肝损伤。入院第3天肝活检后,给予甲基强的松龙(1000 mg)。肝脏组织学显示急性肝炎伴弥漫性小叶炎症/坏死,门静脉区以淋巴细胞为主浸润。根据日本消化疾病周刊2004 (DDW-J)量表,评估时间关系、肝活检和实验室检查结果,诊断患者为COVID-19疫苗引起的药物性肝损伤。随着血液检查参数的改善,泼尼松龙逐渐逐渐减少并停止使用。一个月后,没有发现复发的生化迹象。据我们所知,这是日本首次出现辉瑞新冠疫苗接种后肝损伤的报告。版权所有©2022日本肝病学会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。